March 13, 2017 Deadline in Lawsuit for Investors in NASDAQ: SGEN Shares Against Seattle Genetics, Inc. Announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / February 27, 2017 / The Shareholders Foundation, Inc. announces that a deadline is coming up on March 13, 2017 in the lawsuit that was filed for certain investors in NASDAQ: SGEN shares over alleged violations of Securities Laws by Seattle Genetics.

Investors who purchased shares of Seattle Genetics, Inc. (NASDAQ: SGEN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

On December 27, 2016, Seattle Genetics, Inc. announced that it had received notice from the U.S. Food and Drug Administration (“FDA”) that a clinical hold or partial clinical hold had been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML).

On January 10, 2017, a lawsuit was filed against Seattle Genetics over alleged securities laws violations. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that vadastuximab talirine presents a significant risk of fatal hepatotoxicity, that as such, Seattle Genetics had overstated the viability of vadastuximab talirine as an acute myeloid leukemia (AML) treatment, and that as a result of the foregoing, Seattle Genetics’ public statements were materially false and misleading at all relevant times.

Those who purchased Seattle Genetics, Inc. (NASDAQ: SGEN) shares should contact the Shareholders Foundation, Inc. at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:

Shareholders Foundation, Inc.

Michael Daniels

+1 (858) 779-1554

mail@shareholdersfoundation.com

3111 Camino Del Rio North

Suite 423

San Diego, CA 92108

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 456014